 Studies have been conducted in several countries with different health care system models to assess the cost @-@ effectiveness of linezolid compared to glycopeptides such as vancomycin or teicoplanin . In most countries , linezolid was more cost @-@ effective than comparable antibiotics for the treatment of hospital @-@ acquired pneumonia and complicated skin and skin structure infections , either due to higher cure and survival rates or lower overall treatment costs . 
